Global Leading Market Research Publisher QYResearch announces the release of its latest report “Gene Expression Microarray Scanner – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Gene Expression Microarray Scanner market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Gene Expression Microarray Scanner was estimated to be worth US22.4millionin2025andisprojectedtoreachUS22.4millionin2025andisprojectedtoreachUS27.8 million by 2032, growing at a CAGR of 3.2% from 2026 to 2032. For genomics core lab directors, biotech R&D managers, and diagnostic service providers, the core business imperative lies in deploying gene expression microarray scanners that address the critical need for high-precision, high-throughput optical imaging of fluorescently labeled cDNA or cRNA hybridized to microarray slides (Agilent, Affymetrix, Illumina BeadChip), enabling accurate quantification of gene expression levels (transcript abundance) for applications in medical diagnosis (cancer subtyping, biomarker discovery, pharmacogenomics, infectious disease), drug development (toxicogenomics, preclinical safety assessment, target identification), breeding (plant and animal genomic selection), and other research (developmental biology, neuroscience, environmental toxicology). The scanner detects fluorescence emission (Cy3, Cy5, Alexa Fluor dyes) using laser excitation (532nm green, 635nm red), photomultiplier tube (PMT) or CCD (charge-coupled device) detection, and confocal optics. Scanners vary by throughput (slide capacity: 1-48 slides per run, automated loading), resolution (2-10 µm), dynamic range (4-6 logs), sensitivity (0.1-1 fluorophores/µm²), and reproducibility (CV <5-10%). Types: high throughput scanner (48-96 slides per batch, automated, for core labs, sequencing centers) and low/medium throughput scanner (1-12 slides, benchtop, for smaller labs).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/releases/6093270/gene-expression-microarray-scanner
The Gene Expression Microarray Scanner market is segmented as below:
Agilent
Thermo Fisher Scientific
illumina
Molecular Devices
Innopsys
Beijing Boao Crystal Code Biotechnology
Centrillion Technology
Segment by Type
High Throughput Scanner
Low/Medium Throughput Scanner
Segment by Application
Medical Diagnosis
Drug Development
Breeding
Other
1. Market Drivers: Microarray Decline? (vs RNA-seq), Legacy installed base, and Diagnostic Applications
Several powerful forces are driving the gene expression microarray scanner market:
Installed base replacement and service – Microarrays widely used 2000-2015 (millions of slides). Legacy scanners aging (10-15 years). Replacement, service, refurbished.
Clinical diagnostic (CE-IVD, FDA) microarray tests – Cancer gene expression profiling (MammaPrint (Agilent), Oncotype DX (Genomic Health), not scanner). Regulatory approved tests require specific scanner model (validated).
Breeding and agricultural genomics – Solid-phase genotyping (SNP chips) not gene expression. But service revenue.
Recent market data (December 2025): According to Global Info Research analysis, high throughput scanners dominate with approximately 70% revenue share (core labs, service providers). Low/medium throughput 30% share (R&D labs). Medical diagnosis (clinical) largest application (40% share). Drug development (pharma) 30% share. Breeding (agriculture) 15% share. Other 15%. North America largest market (45% share) (Agilent, Thermo Fisher, Illumina). Europe 25% share. Asia-Pacific 20% share. Supply: Agilent (SureScan), Thermo Fisher (GeneTitan, Affymetrix), Illumina (iScan, BeadArray Reader), Molecular Devices (GenePix), Innopsys (France), Beijing Boao (China), Centrillion (US). GenePix (Molecular Devices) legacy.
2. Scanner Types and Specifications
| Type | Slide Capacity (per run) | Scan Time (per slide) | Resolution (µm) | Dynamic Range | Automation | Price (USD) | Share |
|---|---|---|---|---|---|---|---|
| High Throughput | 48-96 | 5-10 minutes | 2-5 | 4-6 logs | Autoloader, barcode reader | US$100,000-300,000 | ~70% |
| Low/Medium Throughput | 1-12 | 10-15 minutes | 2-10 | 4-5 logs | Manual | US$50,000-150,000 | ~30% |
Key specifications: Excitation lasers (532nm (Cy3), 635nm (Cy5), 488nm (FITC), 594nm (Cy3.5), 594nm for other dyes). Detection (PMT, CCD). Chip compatibility (Agilent 1x1M, 4x44K, 8x15K; Affymetrix GeneChip (cartridge), Illumina BeadChip, custom slides). Image analysis software (Agilent Feature Extraction, Affymetrix Expression Console, Illumina GenomeStudio, GenePix Pro). Data export (TIFF, TXT, CSV). Calibration (fluorescent reference slide). Maintenance (cleaning, laser alignment).
Exclusive observation (Global Info Research analysis): Gene expression microarray scanner market is mature and declining due to RNA-seq displacement, but stable (clinical diagnostics, legacy). Agilent (SureScan), Thermo Fisher (GeneTitan), Illumina (iScan) market leaders. Molecular Devices (GenePix) niche (spotted arrays). Innopsys (France) also. Beijing Boao (China) domestic low-cost scanner.
User case – clinical microarray (December 2025): Reference lab (EU) uses CE-IVD microarray (Agilent 8x60K) for cancer subtyping (breast). Scanner: Agilent SureScan Dx. Process 48 slides/day. Results to oncologist.
User case – genotyping (breeding) (January 2026): Plant breeding institute (India) uses Illumina iScan for SNP genotyping (BeadChip). Not gene expression. Scanner infrastructure.
3. Technical Challenges
Competition from RNA-seq – NGS (RNA-seq) provides higher dynamic range, novel transcript discovery. RNA-seq cost decreased (US$100-200 per sample). Microarray use declines.
Clinical validation (FDA) – Scanner must be validated for diagnostic use (FDA 510(k) clearance). Instrument compatibility (assay-specific).
Technical difficulty – PMT saturation: Strong fluorescent signal saturates PMT (non-linear). Dynamic range.
Technical development (October 2025): Innopsys (France) introduced InnoScan 1100 AL (low autofluorescence, high sensitivity). Compatible with Agilent, Affymetrix, custom arrays.
4. Competitive Landscape
Key players include: Agilent (US – SureScan), Thermo Fisher Scientific (US – GeneTitan), Illumina (US – iScan), Molecular Devices (US – GenePix), Innopsys (France), Beijing Boao Crystal Code Biotechnology (China), Centrillion Technology (US). Agilent, Thermo Fisher, Illumina leaders.
Regional dynamics: North America (Agilent, Thermo Fisher, Illumina, Molecular Devices). Europe (Innopsys). China (Beijing Boao).
5. Outlook
Gene expression microarray scanner market will grow at 3.2% CAGR to US$27.8 million by 2032, driven by clinical diagnostics (CE-IVD, FDA), legacy replacement, and agricultural breeding. RNA-seq continues to displace discovery gene expression, but microarrays remain for large sample sets (cost), known transcripts. Technology trends: higher throughput (automated), sensitivity (PMT/CCD improvement), and lower cost (CCD scanners). Asia-Pacific growth (4-5% CAGR).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
